Regeneron Pharmaceuticals (REGN)
Nasdaq Market Closed
Regeneron Pharmaceuticals Inc is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious diseases. The company is best known for its internally developed research platforms and for building a portfolio that spans ophthalmology, immunology, oncology, cardiovascular disease, inflammation, and rare conditions. Its approach combines genetics, antibody science, and biologics manufacturing, allowing it to move drug candidates from early discovery through clinical development and commercialization.
Regeneron’s ophthalmology franchise includes Eylea and Eylea HD, treatments used for wet age-related macular degeneration and other retinal diseases. These products have been central to the company’s revenue base and are marketed through a major collaboration with Bayer outside the United States. In immunology, Regeneron co-develops and commercializes Dupixent with Sanofi. Dupixent is used across several type 2 inflammatory diseases and is one of the most important products in the company’s portfolio.
The company also markets or partners on products such as Praluent for lowering LDL cholesterol, Libtayo in cancer treatment, Kevzara for rheumatoid arthritis, and Lynozyfic for multiple myeloma. Its pipeline includes additional antibody-based medicines and other biologic candidates, reflecting a strategy of expanding approved drugs into new indications while advancing new therapies from its research engine.
Regeneron competes in markets where innovation, clinical data, patent protection, payer access, and physician adoption are critical. Investors typically watch the durability of the Eylea franchise, growth from Dupixent, progress in oncology and hematology, and the company’s ability to replenish its pipeline as products mature. Its combination of profitable marketed drugs and substantial research capacity makes it a significant name in the global biotech sector.
Last updated
- Market Cap
- $70,943,524,564
- P/E
- 16.04
- P/FCF
- 17.25
- P/S
- 4.76
- Enterprise Value
- $70,687,124,564
- Sector
- Health Care
- Industry
- Biotechnology
- Address
- 777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, 10591
The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea
3 High-Yield Dividend Stocks to Buy and Hold
Merck Snags A First-Of-Its-Kind Approval, And Shares Jump
Merck Gets Approval for Powerful Cholesterol-Cutting Pill
1 Large-Cap Stock with Exciting Potential and 2 We Turn Down
Disappointing Trial Results Hurt Regeneron Pharmaceuticals (REGN) in Q2
Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight
Parabilis Medicines Announces Pricing of Upsized Initial Public Offering
Treg Cell-Based Therapies Clinical Trial Pipeline Appears Robust With 29+ Key Pharma Companies Actively Working in the Domain | DelveInsight
Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
Regeneron stock drops double digits on oncology trial failure
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma
UPDATE – Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Neomorph Announces Closing of $100 Million Series B Financing
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $70,943,524,564
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- $70,687,124,564
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 16.04
- P/B
P/B ratio compares a company's share price to its book value per share.
- 2.26
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 4.76
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 17
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 4.74
- EPS
- 42.19
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0.53%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 17.25
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 14.15
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- $4,113,000,000
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 14.08%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 10.82%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.09
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 3.57
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 2.96
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.58
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- $956,496
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 676.69
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 3.61B | 3.88B | 3.75B | 3.68B | 3.03B |
| Cost of revenue | 669.4M | 584.6M | 521.6M | 275.6M | 464.3M |
| Gross profit | 2.94B | 3.3B | 3.23B | 3.4B | 2.56B |
| Operating income | 642.9M | 869.9M | 1.03B | 1.08B | 591.7M |
| EBITDA | 766.1M | 1.01B | 1.16B | 1.21B | 718.6M |
| Net income | 727.2M | 844.6M | 1.46B | 1.39B | 808.7M |
| Income taxes | 104M | 199.1M | 303.3M | 127.1M | 96.3M |
| Interest expense | -12.9M | -12.2M | -19.3M | -3.6M | -8.7M |
| Other operating expenses | 0 | 0 | -10M | 254.6M | 0 |
| Total operating expenses | 2.29B | 2.43B | 2.21B | 2.32B | 1.97B |
| Basic EPS | 6.99 | 8.24 | 14.09 | 13.24 | 7.58 |
| Diluted EPS | 6.75 | 7.87 | 13.62 | 12.81 | 7.27 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 40.87B | 40.56B | 40.17B | 38.22B | 37.55B |
| Total liabilities | 9.45B | 9.3B | 9.21B | 8.28B | 8.16B |
| Total equity | 31.42B | 31.26B | 30.96B | 29.94B | 29.39B |
| Cash & equivalents | 2.96B | 3.12B | 2.51B | 2B | 3.09B |
| Current assets | 18.21B | 18.02B | 17.98B | 16.86B | 17.57B |
| Current liabilities | 5.11B | 4.37B | 4.43B | 3.67B | 3.57B |
| Accounts payable | 1.03B | 939M | 903.8M | 723.9M | 705.5M |
| Receivables | 5.73B | 5.74B | 5.69B | 5.61B | 5.56B |
| Inventories | 3.1B | 3.2B | 3.25B | 3.21B | 3.19B |
| Long-term debt | 1.99B | 2.71B | 2.71B | 2.71B | 2.7B |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | 1.08B | 1.17B | 1.62B | 1.14B | 1.05B |
| Investing cash flow | -428.9M | 220.3M | -402.9M | -1.09B | 647.5M |
| Financing cash flow | -802.2M | -780.1M | -717.9M | -1.13B | -1.09B |
| Change in cash | -153.1M | 610.6M | 497.5M | -1.08B | 604M |
| Net income | 727.2M | 844.6M | 1.46B | 1.39B | 808.7M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — REGENERON PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 8-K — REGENERON PHARMACEUTICALS, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 144 — REGENERON PHARMACEUTICALS, INC. | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| edgar index | 8-K — REGENERON PHARMACEUTICALS, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 13F-HR — REGENERON PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 4 — REGENERON PHARMACEUTICALS, INC. | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| edgar index | SCHEDULE 13G — REGENERON PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 8-K — REGENERON PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 10-Q — REGENERON PHARMACEUTICALS, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | ARS — REGENERON PHARMACEUTICALS, INC. | View Filing | |
| edgar index | DEF 14A — REGENERON PHARMACEUTICALS, INC. | View Filing | |
| edgar index | DEFA14A — REGENERON PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 8-K — REGENERON PHARMACEUTICALS, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — REGENERON PHARMACEUTICALS, INC. | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| edgar index | SCHEDULE 13G/A — REGENERON PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 4 — REGENERON PHARMACEUTICALS, INC. | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing | |
| edgar index | 4 — REGENERON PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 144 — REGENERON PHARMACEUTICALS, INC. | View Filing | |
| form 4 | Form 4 — Zoghbi Huda Y | View Filing | |
| form 4 | Form 4 — Zoghbi Huda Y | View Filing | |
| form 4 | Form 4 — Zoghbi Huda Y | View Filing | |
| form 4 | Form 4 — Zoghbi Huda Y | View Filing | |
| form 4 | Form 4 — Zoghbi Huda Y | View Filing | |
| form 4 | Form 4 — Zoghbi Huda Y | View Filing | |
| form 4 | Form 4 — Zoghbi Huda Y | View Filing | |
| form 4 | Form 4 — Zoghbi Huda Y | View Filing | |
| form 4 | Form 4 — Zoghbi Huda Y | View Filing | |
| form 4 | Form 4 — Zoghbi Huda Y | View Filing | |
| form 4 | Form 4 — Zoghbi Huda Y | View Filing | |
| form 4 | Form 4 — Zoghbi Huda Y | View Filing | |
| form 4 | Form 4 — Zoghbi Huda Y | View Filing | |
| edgar index | 4 — REGENERON PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 4 — REGENERON PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 144 — REGENERON PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 144 — REGENERON PHARMACEUTICALS, INC. | View Filing | |
| form 4 | Form 4 — RYAN ARTHUR F | View Filing |
- Trusted by 1M+ investors
- Global coverage
- Real-time market data
- Independent & unbiased
Join thousands making smarter investment decisions.
Get started for free